Favorable Safety Profile

Limbrel® 500 (flavocoxid and citrated zinc bisglycinate) 500 mg/50 mg

Efficacy Across Multiple Patient Types

... for the dietary management of osteoarthritis

Decreased concomitant use of PPI or H-2 blockers in prior users [1]

Use of PPI / H2 after starting Limbrel	% of Baseline NSAID Users who Used PPI or H2s (N=306)
Discontinued	6%
Decreased	25%
About the Same	59%
Increased	5%

- *Almost 50% of previous NSAID users had used PPI or H-2s[1]*
- *Of these PPI/H-2 users, 31% decreased or discontinued use of PPI or H-2s with Limbrel therapy[1]*

Study Description: GOAL open label survey conducted at 41 multi-center, rheumatology practices. Patients with osteoarthritis (OA) of any joint (n=1067) were administered Limbrel 500 mg BID for 60 days. Patients who had used NSAIDs and/or gastro-protective medication were not excluded from the study.

Introducing GOAL: Gauging OA with Limbrel

A post market, multi-center real world survey of more than 1000 patients using Limbrel

VAS scores improved for 65.8% of all patients using Limbrel [1]

Physician Global Assessment of Disease (PGAD)



* VAS = Visual Analog Scale
0 = Best and 100 = Worst
Group improvement was statistically significant at 2 months vs. baseline ($p < 0.001$)
N = 1005

More than half the patients experienced improvement in key OA measures [1]

Areas of patient improvement in OA measures: [1]				
Baseline Month vs. 2	*Joint Discomfort*	*Stiffness*	*Mobility*	*Quality of Life*
% Somewhat or Much Better	59% (n=588)	56% (n=564)	54% (n=543)	55% (n=556)

Study Description: GOAL open label survey conducted at 41 multi-center, rheumatology practices. Patients with osteoarthritis (OA) of any joint (n=1067) were administered Limbrel 500 mg BID for 60 days. Patients who had used NSAIDs and/or gastro-protective medication were not excluded from the study.

Prescribe Limbrel for your Osteoarthritis patients

**Also in 250-50 mg BID.*

Limbrel® 500 (flavocoxid™ and citrated zinc bisglycinate) 500 mg/50 mg

Free to Move Again®

References:
1. Pillai L, Burnett BP, Levy RM for the GOAL Study Cooperative Group. Open-Label, Post-Marketing Study of Flavocoxid, a Novel Dual Pathway Inhibitor Anti-Inflammatory Agent of Botanical Origin: The GOAL Study. *Current Medical Research and Opinion*. 2010. 26 (5): 1055-1063

PRIMUS PHARMACEUTICALS

Limbrel 500
(flavocoxid and citrated zinc bisglycinate) 500 mg/50 mg

Efficacy Across Multiple Patient Types

Significant improvement in the signs and symptoms of OA with Limbrel[1]

Physician Global Assessment of Disease (PGAD)



* VAS = Visual Analog Scale
All between group differences and each group's improvement over baseline was significant ($p < 0.001$).

Patients with moderate to severe OA showed the most improvement in VAS scores [1]

Physician Global Assessment of Disease (PGAD)



* VAS = Visual Analog Scale
All groups reported a significant improvement over baseline ($p < 0.001$)

Worked well with both NSAID naïve and NSAID non-responder patients [1]

Study Description: GOAL open label survey conducted at 41 multi-center, rheumatology practices. Patients with osteoarthritis (OA) of any joint (n=1067) were administered Limbrel 500 mg BID for 60 days. Patients who had used NSAIDs and/or gastro-protective medication were not excluded from the study.

Favorable Safety Profile

Limbrel is well tolerated [1]

Patients stopped therapy due to GI tolerability issues



Limbrel was tolerated in 90% of patients with a prior history of NSAID induced GI events [1]

Upper GI tolerability	
% of Baseline NSAID Users (N=646)	Upper GI Tolerability
Better or Much Better	48%
About the Same	43%
Worse or Much Worse	7%

**Totals do not add up to 100% due to a small percentage of "not reported" for this question.*

48% of patients who had GI problems on NSAIDs tolerated Limbrel better [1]

Study Description: GOAL open label survey conducted at 41 multi-center, rheumatology practices. Patients with osteoarthritis (OA) of any joint (n=1067) were administered Limbrel 500 mg BID for 60 days. Patients who had used NSAIDs and/or gastro-protective medication were not excluded from the study.